5 news items
B. Riley Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $200
MDGL
10 May 24
B. Riley Securities analyst Mayank Mamtani maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $270 to $200.
HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $390
MDGL
8 May 24
HC Wainwright & Co. analyst Ed Arce maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $425 to $390.
Citigroup Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $382
MDGL
8 May 24
Citigroup analyst David Lebovitz maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $389 to $382.
JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $381
MDGL
8 May 24
JMP Securities analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and lowers the price target from $397 to $381.
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
MDGL
16 Apr 24
-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit
- Prev
- 1
- Next